Surrogate markers in antiangiogenesis clinical trials

por Davis, D W, McConkey, D J, Abbruzzese, J L, Herbst, R S
Publicado 2003

2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.

por Ellerhorst, J. A., Frost, P., Abbruzzese, J. L., Newman, R. A., Chernajovsky, Y.
Publicado 1993

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine

por Overman, M J, Pozadzides, J, Kopetz, S, Wen, S, Abbruzzese, J L, Wolff, R A, Wang, H
Publicado 2010

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

por Ko, A H, Hwang, J, Venook, A P, Abbruzzese, J L, Bergsland, E K, Tempero, M A
Publicado 2005

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

por Reid, T, Galanis, E, Abbruzzese, J, Sze, D, Andrews, J, Romel, L, Hatfield, M, Rubin, J, Kirn, D
Publicado 2001

A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer

por Hoff, P M, Kopetz, S, Thomas, M B, Langleben, A, Rinaldi, D, Anthony, L, Wolff, R A, Lassere, Y, Abbruzzese, J L
Publicado 2008